PURPOSE: To assess the efficacy and tolerability of interferon (IFN) alpha-2a in post-infectious uveitis secondary to presumed intraocular tuberculosis (IOTB). METHODS: Patients with chronic uveitis secondary to presumed IOTB who, after completing an antitubercular treatment, showed poor response to treatments or recurred after tapering oral corticosteroids to ≤7.5 mg/day were enrolled. All patients were treated with IFN alpha-2a subcutaneous injections. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), and inflammatory signs were compared between baseline and follow-up visits up to six months. RESULTS: Twelve eyes (six patients) were enrolled. Mean BCVA improved from 0.64 ± 0.55 logMAR at baseline to 0.32 ± 0.31 logMAR at 6 months (p = 0.03). Mean CRT decreased from 372 ± 132.2 μm to 274.66 ± 34.9 μm at six months (p = 0.01). Inflammatory signs (vitritis, vasculitis) also decreased overtime. No major complications or tuberculosis reactivations were recorded. CONCLUSIONS: IFN alpha-2a was efficacious and safe in treating chronic post-infectious uveitis secondary to presumed IOTB.

Interferon Alpha-2a for the Treatment of Post-Infectious Uveitis Secondary to Presumed Intraocular Tuberculosis / Invernizzi, Alessandro; Iannaccone, Franca; Marchi, Sylvia; Mastrofilippo, Valentina; Coassin, Marco; Fontana, Luigi; Salvarani, Carlo; McCluskey, Peter; Cimino, Luca. - In: OCULAR IMMUNOLOGY AND INFLAMMATION. - ISSN 0927-3948. - 27:4(2019), pp. 643-650. [10.1080/09273948.2018.1431292]

Interferon Alpha-2a for the Treatment of Post-Infectious Uveitis Secondary to Presumed Intraocular Tuberculosis

Salvarani, Carlo;Cimino, Luca
2019

Abstract

PURPOSE: To assess the efficacy and tolerability of interferon (IFN) alpha-2a in post-infectious uveitis secondary to presumed intraocular tuberculosis (IOTB). METHODS: Patients with chronic uveitis secondary to presumed IOTB who, after completing an antitubercular treatment, showed poor response to treatments or recurred after tapering oral corticosteroids to ≤7.5 mg/day were enrolled. All patients were treated with IFN alpha-2a subcutaneous injections. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), and inflammatory signs were compared between baseline and follow-up visits up to six months. RESULTS: Twelve eyes (six patients) were enrolled. Mean BCVA improved from 0.64 ± 0.55 logMAR at baseline to 0.32 ± 0.31 logMAR at 6 months (p = 0.03). Mean CRT decreased from 372 ± 132.2 μm to 274.66 ± 34.9 μm at six months (p = 0.01). Inflammatory signs (vitritis, vasculitis) also decreased overtime. No major complications or tuberculosis reactivations were recorded. CONCLUSIONS: IFN alpha-2a was efficacious and safe in treating chronic post-infectious uveitis secondary to presumed IOTB.
2019
22-feb-2018
27
4
643
650
Interferon Alpha-2a for the Treatment of Post-Infectious Uveitis Secondary to Presumed Intraocular Tuberculosis / Invernizzi, Alessandro; Iannaccone, Franca; Marchi, Sylvia; Mastrofilippo, Valentina; Coassin, Marco; Fontana, Luigi; Salvarani, Carlo; McCluskey, Peter; Cimino, Luca. - In: OCULAR IMMUNOLOGY AND INFLAMMATION. - ISSN 0927-3948. - 27:4(2019), pp. 643-650. [10.1080/09273948.2018.1431292]
Invernizzi, Alessandro; Iannaccone, Franca; Marchi, Sylvia; Mastrofilippo, Valentina; Coassin, Marco; Fontana, Luigi; Salvarani, Carlo; McCluskey, Pet...espandi
File in questo prodotto:
File Dimensione Formato  
invernizzi2018.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 1.25 MB
Formato Adobe PDF
1.25 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1155272
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 14
social impact